Marc Beer is the founder of Renovia Inc. Renovia will produce a few innovative products for pelvic floor disorders since closing a $32 million Series B round on Tuesday with $10 million venture debt. Renovia is a Boston based company that is creating several therapeutic and diagnostic products these products are created to help pelvic floor disorders such as urinary incontinence, which is estimated to affect 250 million females globally. Renovia’s first product to be reviewed is Leva. It was approved by the FDA in April.
The Early Investor
Renovia was invested in early by The Longwood Fund. The Longwood Fund is an investing firm focused on healthcare that joined the Series B round. The funding will be contributing to testing and development four additional therapeutic and diagnostic products, which includes an upgrade of the Leva device. Marc Beer says Renovia is excited to have the support of Longwood, who also care about the ability to better treat, improve and diagnose tons of women who are affected daily by pelvic floor issues. The addition of a digital health platform will provide the customers with valuable data to advise them on options for breakthrough treatments, better education and understanding of the pelvic floor issues as well as reduced healthcare costs over time.
About Marc Beer
Marc Beer has over 25 years of experience in biotech, pharmaceuticals, diagnostics and devices. He co-founded Renovia with Yolanda Lorie and Ramon Iglesias, MD in 2016. Renovia is the first thing Marc Beer created since he left Aegerion in 2015. He was there for five years and created a drug to aid an uncommon form of high cholesterol. The company is now a part of Novelion Theerapeutics, a Canadian company. The medicine Juxtapid was approved by the FDA and is an effective treatment. Marc was also a strategic advisor for OvaScience. This company has announced that it plans to merger with Millendo Therapeutics, a Michigan company. Learn more : https://www.slideshare.net/MarcBeer